Effects of dopamine antagonists on methamphetamine-induced dopamine release in high and low alcohol preference rats. 2010

Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
Department of Legal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. nishig@hyo-med.ac.jp

The authors have previously shown that high alcohol preference rats (HAP) have a significantly higher sensitivity than low alcohol preference rats (LAP) for methamphetamine (MAP). In this study, changes in dopamine and serotonin release induced by MAP (1 mg/kg, intraperitoneally) after pre-treatment with D1 and D2 receptor antagonists were examined in the striatum of rats with different alcohol preferences to elucidate differences in receptor levels between the two rat strains. D1 receptor antagonist SCH23390 or D2 receptor antagonist haloperidol were administrated intracerebroventricularly 10 min before MAP stimulation. This study investigated the effect of methamphetamine-induced dopamine and serotonin release in striatum using microdialysis of freely moving rats coupled to ECD-HPLC. With haloperidol treatment both strains of rats showed a significantly greater maximum increase on MAP-induced dopamine release compared with respective control rats. However, after SCH23390 treatment only HAP rats showed a significantly greater increase in dopamine release compared with controls. SCH23390 blocks mainly D1 receptors only in the post-synaptic membrane, whereas haloperidol blocks D2 receptors in both the pre-synaptic and post-synaptic membranes. The MAP-induced increase in dopamine release following haloperidol pre-treatment was greater than SCH23390 pre-treatment in both strains. This result indicates that D2 receptors (autoreceptors) in the pre-synaptic membrane were blocked, leading to the elimination of the feedback function that regulates dopamine release. These data suggested that alcohol preference is associated with the action of MAP, and the dopaminergic mechanism, specifically the D1 system in the striatum, might have a different pathway dependent on alcohol preference.

UI MeSH Term Description Entries
D008694 Methamphetamine A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed. Deoxyephedrine,Desoxyephedrine,Desoxyn,Madrine,Metamfetamine,Methamphetamine Hydrochloride,Methylamphetamine,N-Methylamphetamine,Hydrochloride, Methamphetamine,N Methylamphetamine
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D000431 Ethanol A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in ALCOHOLIC BEVERAGES. Alcohol, Ethyl,Absolute Alcohol,Grain Alcohol,Alcohol, Absolute,Alcohol, Grain,Ethyl Alcohol
D000437 Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4) Alcohol Abuse,Alcoholic Intoxication, Chronic,Ethanol Abuse,Alcohol Addiction,Alcohol Dependence,Alcohol Use Disorder,Abuse, Alcohol,Abuse, Ethanol,Addiction, Alcohol,Alcohol Use Disorders,Chronic Alcoholic Intoxication,Dependence, Alcohol,Intoxication, Chronic Alcoholic,Use Disorders, Alcohol
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001552 Benzazepines Compounds with BENZENE fused to AZEPINES.
D012701 Serotonin A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, hemostasis, and cardiovascular integrity. Multiple receptor families (RECEPTORS, SEROTONIN) explain the broad physiological actions and distribution of this biochemical mediator. 5-HT,5-Hydroxytryptamine,3-(2-Aminoethyl)-1H-indol-5-ol,Enteramine,Hippophaine,Hydroxytryptamine,5 Hydroxytryptamine

Related Publications

Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
May 1996, Journal of neurochemistry,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
March 2008, Biochemical pharmacology,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
February 2001, Brain research,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
April 2004, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
February 1992, Arukoru kenkyu to yakubutsu izon = Japanese journal of alcohol studies & drug dependence,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
September 1995, European journal of pharmacology,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
September 2005, Psychopharmacology,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
December 2020, Experimental brain research,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
October 1996, The Journal of pharmacology and experimental therapeutics,
Minori Nishiguchi, and Hiroshi Kinoshita, and Shogo Kasuda, and Montonori Takahashi, and Takehiko Yamamura, and Kiyoshi Matsui, and Harumi Ouchi, and Takako Minami, and Shigeru Hishida, and Hajime Nishio
January 1987, Journal of psychopharmacology (Oxford, England),
Copied contents to your clipboard!